Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH -4.33% Revenue per Share is $0.47 as of Jun. 2026. The stock has 6 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 99.48% on this metric.
ProPhase Labs's revenue per share for the
three
months ended in Jun. 2026 was $0.07.
ProPhase Labs's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.47.
Warning Sign:
ProPhase Labs Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of ProPhase Labs was -77.50% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -80.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -50.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 4.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for ProPhase Labs's Revenue per Share or its related term are showing as below:
PRPH'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -80.2 Med: -0.4 Max: 124.1
Current: -80.2
During the past 13 years, ProPhase Labs's highest 3-Year average Revenue Per Share Growth Rate was 124.10% per year. The lowest was -80.20% per year. And the median was -0.40% per year.
PRPH's 3-Year Revenue Growth Rate is ranked worse than 99.48% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.9
vs PRPH: -80.20
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
ProPhase Labs Revenue per Share Related Terms
ProPhase Labs Revenue per Share Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs IDTA, NSTM, NOTVQ: Revenue per Share Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
ProPhase Labs's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProPhase Labs (PRPH) has a Revenue per Share of $0.47 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on ProPhase Labs and its competitors. According to the industry distribution chart, ProPhase Labs ranks #190 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is ProPhase Labs' Revenue per Share too high?
ProPhase Labs' current Revenue per Share is $0.47. The Medical Diagnostics & Research industry median Revenue per Share is 1.90. ProPhase Labs' value of $0.47 is 75.3% below this industry median. Based on the distribution chart, ProPhase Labs ranks #190 out of 191 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Revenue per Share compare to IDTA and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #190 out of 191 companies for Revenue per Share. This places ProPhase Labs in the lower half of its industry. The industry median Revenue per Share is 1.90. ProPhase Labs' value of $0.47 is 75.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Diagnostics & Research company?
The median Revenue per Share among Medical Diagnostics & Research companies is 1.90, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Revenue per Share of $0.47 is 75.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Revenue per Share is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Revenue per Share is $0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.02 — trading 96.3% below its estimated fair value. The current Revenue per Share is $0.47 and 75.3% below the Medical Diagnostics & Research industry median of 1.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Revenue per Share is $0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
